Integra LifeSciences Presents Real-World Data on PriMatrix Across Major Wound Care Conferences
Event summary
- Integra LifeSciences will present new real-world data on PriMatrix® Dermal Scaffold at three major medical conferences in April 2026.
- Data includes analyses from 985 cases involving 117 surgeons, covering a broad range of wound types, including surgical, traumatic, and chronic ulcers.
- A 23-patient case series outlines clinical experience with PriMatrix in burn injuries, including patients with significant comorbidities.
- Key presentations include insights on diabetic foot ulcers, real-world utilization, complex wounds, and burn injuries.
The big picture
Integra LifeSciences is reinforcing its position in the wound care market by showcasing real-world evidence for PriMatrix across multiple conferences. This strategy aligns with broader industry trends towards evidence-based medical technologies, particularly in specialized fields like wound reconstruction and burn care. The company's ability to present data from a large number of cases and surgeons underscores its commitment to clinical validation and tailored approaches in transformational care.
What we're watching
- Clinical Adoption
- How the increasing volume of clinical use and interest across care settings will impact PriMatrix's market penetration.
- Competitive Positioning
- Whether Integra can sustain its leadership in wound reconstruction with evidence-based solutions.
- Regulatory Dynamics
- The pace at which real-world evidence will influence regulatory approvals and reimbursement policies for PriMatrix.